Axogen Stock (NASDAQ:AXGN), Trade Ideas

Axogen

AXOGEN INC

Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AIMD

AISP

APGE

AVAV

AXGN

BIAF

BRSH

BYSI

CARA

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CECO

CMAX

DAVE

EKSO

EYEN

FUFU

GTLB

LIPO

MNTS

MSTR

NYCB

OCEA

PHUN

POWL

QNRX

RBOT

RNLX

SBFM

SEMR

SFIX

SIDU

SOPH

TDUP

TNDM

VATE

VIVK

XRTX

YGMZ

ZCMD

Shares of  SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance.

Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Earnings

Eurozone

Commodities

Global

APLT

BNZI

RCAC

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 50 points on Friday.

The Dow traded up 0.13% to 37,490.36 while the NASDAQ rose 0.25% to 14,546.77. The S&amp;P 500 also rose, gaining, 0.26% to 4,701.05.

Crude Oil Rises Over 2%; Constellation Brands Posts Downbeat Sales

ALLO

ANGO

ATXI

CISO

CPRX

CYCC

DRMA

ELAN

EXAI

IMCR

Intelligent Bio Solutions Inc. - Common Stock

INBS

KORE

KRUS

LSDI

NEXI

OMGA

PNST

PTON

PYPD

SABS

SMFL

SWVL

TBPH

VERB

VYGR

Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Axogen Inc

AxoGen Non-GAAP EPS of -$0.06 beats by $0.02, revenue of $42.9M beats by $1.9M

An announcement from AxoGen (AXGN) is now available. Discover the latest financial performance of the Company as they unveil their fourth quarter a...

AxoGen Unveils Q4 and Full Year 2023 Financial Results

AxoGen, Inc Common Stock (AXGN) surpassed earnings projections on 3/5/2024 for Q4 2023. reported that it broke-even during the quarter.   Revenues were downbeat at $0.00.  Keep in mind that the revenues reported were on an adjusted basis, so they may not be directly comparable to estimates and prior periods.The stock is do

Axogen Inc Down 10.07% To $9.52 After Earnings

AxoGen, Inc. (AXGN) Q4 2023 Earnings Call Transcript

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Axogen</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/axgn-stock-quote/"><strong>AXGN</strong></a></span>) just reported results for the fourth quarter of 2023.</p><ul><li>Axogen reported earnings per share of -6 cents. This was above the analyst estimate for EPS of -10 cents.</li><li>The company reported revenue of $42.90 million.</li><li>This was better than the analyst estimate for revenue of $41.65 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793996">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/03/axgn-stock-earnings-axogen-for-q4-of-2023/">AXGN Stock Earnings: Axogen Beats EPS, Beats Revenue for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

AXGN Stock Earnings: Axogen Beats EPS, Beats Revenue for Q4 2023

The latest update is out from AxoGen (AXGN). Axogen Inc. has updated their corporate presentation and made it available on their website for analys...

AxoGen Releases Updated Corporate Presentation Online

Analyst David Turkaly of JMP Securities reiterated a Buy rating on AxoGen (AXGN – Research Report), with a price target of $17.00. David Turkaly ha...

Buy Rating Affirmed: AxoGen's Robust Growth and Market Potential Drive Positive Outlook

AxoGen files $100M mixed securities shelf

Leerink Partners analyst Mike Kratky has reiterated their bullish stance on AXGN stock, giving a Buy rating yesterday. Mike Kratky's rating is base...

Axogen's Strong Growth Prospects and Positive Analyst Outlook Prompt Buy Rating and Increased Price Target

AxoGen (AXGN) has disclosed a new risk, in the Accounting & Financial Operations category. AxoGen may encounter considerable business risk if it fa...

New Accounting & Financial Operations Risk for AxoGen – What's the Latest?

Management

Press Releases

Axogen Announces Transition of Finance Team Leadership

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

Axogen Announces Promotions on Research and Development Team

Health Care

Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

AMWL

AngioDynamics

Accuray

Butterfly Network, Inc. Class A Common Stock

Butterfly Network

ClearPoint Neuro

CVRx

Alpha Tau Medical

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share